Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising ...
FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.
The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...
Regeneron rebounds from regulatory and clinical setbacks as Dupixent and pipeline catalysts fuel growth. Click here to read ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Apogee Therapeutics, Inc. (NASDAQ ...
Opinion
Zacks Investment Research on MSNOpinion
Top analyst reports for Amazon, Intel & Applied Materials
Monday, April 27, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, ...
17hon MSN
Health care roundup: Market talk
Find insight on Roche Holding, AstraZeneca, Sanofi and more in the latest Market Talks covering the Health Care sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results